Emerging Menin Inhibitors and Patient Impact

EP: 1.KMT2A AML Pathogenesis and Presentation

EP: 2.Prognosis and Perception of KMT2A AML

EP: 3.Patient Profiles: Demographics and Disease Biology

EP: 4.Targeting Menin: A New Frontier in AML

EP: 5.Efficacy, Safety, and Experience With Revumenib

EP: 6.Shifts in Standard of Care for Adults and Children With KMT2A AML

Now Viewing

EP: 7.Emerging Menin Inhibitors and Patient Impact

EP: 8.Educating on Menin Inhibitors

EP: 9.The Why and When of Molecular Testing in AML

EP: 10.Delays in Detection and the Impact on Access to Targeted Therapy

The treatment landscape for KMT2A-rearranged AML is undergoing a significant transformation with the emergence of targeted therapies, particularly menin inhibitors. Although only 1 menin inhibitor is currently approved, several others are in development and show encouraging activity in early clinical studies. These include agents being evaluated both as single agents and in combination with other therapies across adult and pediatric populations. Although early data are promising, much remains to be determined regarding the optimal sequencing of these therapies and their potential roles in different molecular subtypes of AML, such as those with NPM1 mutations.

A key focus is understanding resistance patterns—both primary resistance and acquired resistance after initial response. Evidence suggests that some patients who relapse after responding to menin inhibitors harbor secondary mutations, possibly in epigenetic regulators or other pathways. These resistance mechanisms may differ depending on whether the drug is used alone or in combination with chemotherapy. Ongoing preclinical and clinical studies are investigating how specific mutations may predict sensitivity or resistance to different menin inhibitors, which could ultimately guide individualized treatment approaches.

In addition to scientific considerations, real-world factors like global drug access and patient quality of life are also shaping how these therapies will be used. Oral administration, outpatient monitoring, and the potential to avoid intensive chemotherapy represent major shifts in how AML might be managed, particularly for patients with aggressive or relapsed disease. As more data emerge from ongoing pivotal trials and real-world settings, the hope is that these new agents will not only extend survival but also enable more patients to reach curative therapies such as transplant. The next few years are likely to bring critical insights that will help define the most effective and sustainable use of menin inhibitors in AML care.